Bulletin from the Annual Shareholders’ Meeting in Alligator Bioscience AB (publ) on 26 April 2018
Lund, Sweden, 26 April 2018 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, today held an annual shareholders’ meeting. A summary of the resolutions adopted follows below. All resolutions were adopted with the required majority. Resolution on adoption of accounts and distribution of the company’s result The annual shareholders’ meeting resolved to adopt the profit and loss statement and balance sheet as well as the consolidated profit and loss statement and the consolidated balance